Abstract on Nasal Photodisinfection Therapy is Accepted for Presentation at the 19th Annual Scientific Conference of the Canadian Spine Society
Ondine Biomedical Inc., a company dedicated to the development of non-antibiotic, anti-infective therapies for a broad-spectrum of bacterial, viral and fungal infections and to combating increasing antimicrobial resistance, today announced that an abstract highlighting data resulting from the use of Ondine's photodisinfection system has been accepted for presentation at the 19th Annual Scientific Conference of the Canadian Spine Society, February 27 - March 2, 2019, Toronto, Ontario, Canada.
VANCOUVER, British Columbia, Feb. 26, 2019 /PRNewswire-PRWeb/ -- Ondine Biomedical Inc., a company dedicated to the development of non-antibiotic, anti-infective therapies for a broad-spectrum of bacterial, viral and fungal infections and to combating increasing antimicrobial resistance, today announced that an abstract highlighting data resulting from the use of Ondine's photodisinfection system has been accepted for presentation at the 19th Annual Scientific Conference of the Canadian Spine Society, February 27 – March 2, 2019, Toronto, Ontario, Canada.
Data will be highlighted from a quality improvement initiative running from 2009 at a major Vancouver health facility providing a pre-operative photodisinfection therapy to all patients undergoing spinal surgery.
The presentation will include long-term data on efficacy and cost-effectiveness of nasal antimicrobial photodisinfection therapy (aPDT) to reduce surgical site infections.
Details for the abstract presentation are as follows:
Title: Efficacy and Cost-Effectiveness of Photodynamic Therapy in Prevention of Surgical Site Infection Presenter: Daniel Banaszek, M.D. Principle Investigator: John Street, M.D., PhD Session Title: Presentation 54, Abstract 75 Date and Time: Friday, March 1, 2019, 8:30 AM, Concert Hall of Fairmont Royal York Hotel Abstract Contributors: Daniel Banaszek, M.D., University of British Columbia, Vancouver, BC, Canada; Tom Inglis, M.D., University of British Columbia, Vancouver, BC, Canada; Titus Wong, M.D., Vancouver Coastal Health; John Street, M.D., University of British Columbia, Vancouver, BC, Canada and Infection Control Program Surgeons (VSPS), Vancouver Spine Institute, Vancouver, BC, Canada. Location: Fairmont Royal York Hotel, Toronto, Ontario Canada
Ondine's nasal photodisinfection system is a patented, first-in-class, light-activated antimicrobial therapy developed to eradicate a broad spectrum of nasal pathogens without promoting antibiotic resistance, including the 'superbug' methicillin-resistant Staphylococcus aureus (MRSA).
About Post-Surgical Site Infections
Surgical site infections (SSI's) account for 15% of all hospital acquired infections and contribute substantially to morbidity and mortality each year. Up to 5% of surgical patients will develop an SSI in hospital, often resulting from Staphylococcus aureus infection. In many cases this virulent pathogen exhibits multidrug resistance making it increasingly difficult to treat. The evolution of antimicrobial resistance stems from the widespread use of antibiotics including inappropriate use in viral and non-susceptible infections. The relative risk of an SSI is up to 9 times greater in Staphylococcus carriers than in non-carriers. Furthermore, molecular epidemiology has demonstrated that the patient's own nasal microflora are responsible for over 80% of postoperative infections. Existing approaches to eliminating nasal bacteria rely on expensive testing prior to surgery and/or prolonged antibiotic therapies. Compliance with these approaches is often poor, and the development of antibiotic resistance is a very real threat.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is dedicated to the development of non-antibiotic, anti-infective therapies for a broad-spectrum of bacterial, viral and fungal infections. Ondine's antimicrobial program utilizes a platform technology called photodisinfection, a light-activated approach being developed to provide rapid antimicrobial efficacy and reduced risk of antibiotic resistance. Over 65 patents in 21 patent families have been granted or are pending covering various aspects of the technology. Ondine's flagship nasal photodisinfection system has been deployed in Canada for several years, and other applications of the photodisinfection platform are under development, including SinuwaveTM, a photodisinfection product to treat chronic rhinosinusitis, and an endotracheal tube photodisinfection product designed to reduce the incidence of ventilator-associated pneumonia (VAP).
Contact
Ondine Biomedical Inc.
http://www.ondinebio.com
Angelika Vance | 1.604.838.2702 | avance(at)ondinebio.com
SOURCE Ondine Biomedical Inc.
Share this article